Phaseline

Companies › Gyala Therapeutics

Gyala Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GYA01 (CART84)
anti-CD84 chimeric antigen receptor (CAR) T-cell therapy
CD84Phase 1Acute Myeloblastic LeukaemiaMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07471789GYA01 (CART84)Phase 1Acute Myeloblastic LeukaemiaOncologyMay 2029

Targets

CD84 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.